Abstract
Bleeding can occur unexpectedly during antithrombotic therapy. Impaired haemostasis is commonly measured by the bleeding time. We measured it by 3 methods in controls and in anticoagulated animals and related it to their antithrombotic status. In 42 control rats template, tail-tip transection and needle occlusion bleeding times correlated poorly (r=0.05–0.34). The template method had the best range (mean 126.97±SEM sees) and consistency. In 10 control animals it correlated mildly (r=0.55) with venous thrombus in the same animal. Thrombus was measured by its weight deposited on platinum wires (2 cm long, 0.4 mm diameter) set in vein and in artery for 1 h. In respective groups of 10 rats, a decrease of mean thrombogenesis was obtained using aspirin, heparin and low molecular weight heparin in 2 dosages and hirudin in 1 dosage. The drugs reduced mean venous thrombus by 13–86 per cent of the mean control thrombus, and prolonged the mean template bleeding time by 29–199 per cent. The ranking of the drugs according to their increase of template bleeding time was virtually the same as the ranking given by their reduction of thrombus weight (Spearman rank coefficient 0.81, sig 0.007). The transection test produced a similar ranking and similar correlation with thrombus (0.71, sig 0.049). Low molecular weight heparin induced the greatest thrombus reduction (39 per cent) for least prolongation of bleeding time (24 per cent). Arterial thrombus was more variable. The bleeding times and thrombus weight were measured in each animal of 2 groups given aspirin, the template method correlating mildly with venous thrombus reduction (r=0.23, 0.58 respectively), the transection method with arterial (0.74, 0.45) and the occlusion test poorly with either (0.13, 0.22). Bleeding time lengthens with increasing antithrombotic effect of drugs, but not in direct proportion, nor similarly with each drug.
Similar content being viewed by others
References
Quick, A. J. Bleeding time after aspirin ingestion. Lancet 1968; 1:50.
Sise, H. S., Adamis, D., Kimball, D. M. Studies on the anticoagulant phenindione. IV. Its multiphase effect on the coagulation mechanism. J. Lab. & Clin. Med. 1957; 49: 69- 83.
Gimple, L. W., Herman, K., Gold, K., Leinbach, R. C., Coller, B. S., Werner, W., Tsunehiro, Y., Johns, J. A., Ziskind, A. A., Finkelstein, D., Cullen, D. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue type plasminogen activator. Circulation 1989; 80: 581–588.
Hirsh, D. R., Goldhaber, S. Z. Bleeding time and other laboratory tests to monitor the safety and efficiency of thrombolytic therapy. Chest, Supplement, 1990; 97: 124S- 121S.
Dodds, W. J. Joint report of the subcommittes on animal models of hemorrhagic and thrombotic diseases and on platelets. Thrombos. Haemostas. 1982; 48: 106–107.
Dejana, E., Villa, S., de Gaetano, G. Bleeding time in rats: a comparison of different experimental conditions. Thrombos. Haemostas. 1982; 48: 108–11.
Meilke, C. H. Measurement of the bleeding time. Thrombos. Haemostas. 1984; 52: 210–211.
Buchanan, G. R., Holtkamp, C. A. A comparative study of variables affecting the bleeding time using two disposable devices. Am. J. Clin. Pathol. 1989; 91: 45–51.
Gerrard, J. M., Docherty, J. C., Israels, S. J., Cheang, M. S., Bishop, A. J., Kobrinski, N. L., Schrioeder, M. L., Israels, E. D. A reassessment of the bleeding time: association of age, hematocrit, platelet function, Von Willebrand factor, and bleeding time thromboxane B2 with the length of the bleeding time. Clin. Invest. Med. 1989; 12: 165–171.
Koster, T., Caekebeke-Peerlinck Kathelijne, M. J., Briet, E. A randomised and blinded comparison of the sensitivity and the reproducibility of the Ivy and Simplate II bleeding time techniques. Am. J. Clin. Pathol. 1989; 92: 315–320.
Breddin, H. K., Krzywanek, H. J., Rieger, H. “Animal models to detect the risks of bleeding”. 24th Angiologisches Symposium in Kitzbuhel 1989.
Lavelle, S. M., Maclomhair, M. The quantitative reduction by heparin of intravenous thrombosis in normal and hypercoagulable animals. Ir. J. Med. Sci. 1980; 149: 266- 269.
Lavelle, S. M., Maclomhair, M. Arterial thrombosis in rats by platinum wire insertions, ellagic acid and EACA. In Breddin, H. K. and Zimmerman, R. eds. Standardisation of animal models of thrombosis. F. K. Schattauer Verlag, Stuttgart 1983, pp 157–160.
Lavelle S. M., Maclomhair, M. The reliability of thrombotic tendency measured by intravascular wires in the rat. Thromb. Res. 1997; 87: 353–357
Maclomhair M., Lavelle, S. M. The antithrombotic effect of some EUROBIOMAT project test polymers in vivo. Technology and Health Care 1996; 4: 385–388.
Lavelle, S. M., Maclomhair M. The quantitative reduction by acute dose warfarin of venous thrombosis in normal and hyperthrombotic rats. Thromb. Res. 1996; 84: 411–417.
Maclomhair M., Lavelle, S. M. The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat. Irish J. Med. Sci. 1996; 165: 213–218.
Doutremepuich, C., de Seze, C. J. F., le Roy, D., Lalanne, M. C., Anne, M. C. Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation, and coagulation. Haemostasis 1990; 20: 99- 105.
Lavelle, S. M. The role of coumarin-sensitive coagulation factors in the prevention of experimental thrombosis induced by local Shwartzman reaction. Final Technical Status Report, Contracts number DA-91-591-EUC-2715 & 3213, 1964; p 28-30. U.S. Govt.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lavelle, S.M., MacIomhair, M. Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat. Ir. J. Med. Sc. 167, 216–220 (1998). https://doi.org/10.1007/BF02937415
Issue Date:
DOI: https://doi.org/10.1007/BF02937415